Oral cancer treatment potentially advances with the application of C-phycocyanin (C-PC), a powerful antioxidant produced by cyanobacteria. By triggering mechanisms that impair the metabolism of mitochondria and cause cancer cells to initiate apoptosis, this pigment demonstrates potent apoptotic-inducing potentials. Innovative application for C-PC includes integrating it with fibrous scaffolds for long-term release, stimulating tissue regeneration, and lowering inflammation and oxidative damage after surgery. Surgical implants with C-PC, such stents and sutures, provide focused therapy at the locations of oral cancer. In order to enhance the therapeutic uses of C-PC in oral cancer, further studies may investigate genetically modified microalgae. Validating these therapeutic effects and advancing cyanobacterial pigment-based drugs into clinical applications demand further studies.
No takes yet. Share an insight, caveat, or question.
Antonyraj et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: